Iodure (123i) De Sodium Curiumpharma

Sodium Iodide, the active ingredient in Iodure (123i) De Sodium Curiumpharma, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is used for diagnostic imaging of the thyroid and related tissues in patients requiring functional assessment.

GNH USA supplies Iodure (123i) De Sodium Curiumpharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Iodure (Sodium Iodide I‑123) is employed in nuclear medicine to visualize thyroid tissue and assess its function.

- Thyroid imaging: Provides high‑resolution scintigraphic images of thyroid anatomy and iodine uptake. - Evaluation of thyroid function: Quantifies glandular activity to differentiate hyper‑ and hypothyroidism. - Detection of thyroid cancer metastases: Identifies metastatic lesions by highlighting iodine‑avid tissue beyond the thyroid gland.

Adverse reactions may occur following intravenous administration of Iodure.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Headache: mild to moderate, usually resolves spontaneously. - Warmth or flushing: brief sensation at the injection site. - Injection site discomfort: mild pain or irritation. - Transient hypotension: slight drop in blood pressure shortly after dosing.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or anaphylaxis requiring immediate medical attention. - Severe hypotension: marked blood pressure decrease needing intervention. - Radiation‑induced thyroiditis: inflammation of the thyroid gland. - Hematologic abnormalities: rare changes in blood counts. - Pulmonary embolism: extremely rare, presenting with respiratory distress.

Prior to administration, clinicians should evaluate patient‑specific factors and follow radiation safety guidelines.

- Pregnancy: use only if the diagnostic benefit outweighs potential fetal radiation exposure. - Breastfeeding: consider temporary cessation of nursing or assess infant risk. - Renal function: assess because impaired clearance may affect radiation dose. - Thyroid status: avoid in untreated hyperthyroidism unless specifically indicated. - Radiation safety: adhere to institutional protocols for handling and disposal of radioactive material. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium Iodide I‑123 may interact with other agents that affect iodine metabolism or cardiovascular stability.

Major Interactions (Avoid): - Iodine‑containing contrast agents: can interfere with tracer uptake and imaging interpretation. - Thyroid hormone therapy: may alter iodine uptake, reducing diagnostic accuracy. - Antithyroid drugs: can diminish tracer accumulation in the thyroid.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt heart‑rate response during stress testing. - ACE inhibitors: monitor blood pressure for additive hypotensive effects. - Diuretics: observe fluid balance and renal function during administration.